Whether the purpose is biomarker discovery, drug target validation, modified protein measurement, quality control, etc., Biognosys continuously redesigns our technology to reach state-of-the-art results.  Currently, our platform enables:

• Shotgun LC-MS/MS with total proteomes, phospho-peptides and other post-translational modifications
• MRM-assay development within 4-6 weeks for every organism based on a patent protected method
• Screening for all human proteins based on 100,000 pre-made MRM assays
• Highly multiplexed protein quantification
• Reliable statistical data analysis
  
  

Further, Biognosys develops and implements a full protein analysis pipeline that connects quantitative shotgun LC-MS/MS to targeted proteomics with LC-MRM.

The key advantage of our platform is sophisticated software which seamlessly connects the modules into robust and efficient workflows.

Parts of the software are developed in collaboration with the ETH Zurich and were published in high ranking scientific journals (see Publications).